Linoorbitides and enterolactone mitigate inflammation-induced oxidative stress and loss of intestinal epithelial barrier integrity
- 1 November 2018
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 64, 42-51
Abstract
No abstract availableKeywords
Funding Information
- Saskatchewan Health Research Foundation, Canada
This publication has 57 references indexed in Scilit:
- Flaxseed Lignan Complex Administration in Older Human Type 2 Diabetics Manages Central Obesity and Prothrombosis—An Invitation to Further Investigation into Polypharmacy ReductionJournal of Nutrition and Metabolism, 2012
- Linking oxidative stress to inflammation: Toll-like receptorsFree Radical Biology and Medicine, 2010
- Dietary lignan intakes in relation to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) StudyBreast Cancer Research and Treatment, 2009
- Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled TrialGastroenterology, 2008
- The fundamental basis of inflammatory bowel diseaseJournal of Clinical Investigation, 2007
- The PPARγ Agonist Rosiglitazone Impairs Colonic Inflammation in Mice with Experimental ColitisJournal of Clinical Immunology, 2007
- A novel PPARγ gene therapy to control inflammation associated with inflammatory bowel disease in a murine modelGastroenterology, 2003
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Interaction of Junctional Adhesion Molecule with the Tight Junction Components ZO-1, Cingulin, and OccludinJournal of Biological Chemistry, 2000
- Human Intestinal Bacteria Capable of Transforming Secoisolariciresinol Diglucoside to Mammalian Lignans, Enterodiol and Enterolactone.Chemical and Pharmaceutical Bulletin, 2000